Improved Sensitivity Detection of Serum HBsAg and HBsAg Reversion
Eligible age
18–65 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this observational study is to learn about the HBsAg reversion rate at 48 weeks off treatment in HBsAg-negative patients by HBsAg NEXT assay which has improved sensitivity compared to current ARCHITECT HBsAg Assay. The main question it aims to answer is: What's the HBsAg reversion rate at 48 weeks off treatment in HBsAg-negative patients by HBsAg NEXT assay? HBsAg NEXT assay technology (lower limit of detection for HBsAg is 0.005 IU/ml) and current ARCHITECT HBsAg assay (lower limit of detection for HBsAg is 0.05 IU/ml) are applied for HBsAg detection in patients achieving functional cure, and to compare the difference in HBsAg reversion rate 48 weeks off treatment under the two types of criteria.
Sponsor: Huashan Hospital
You may qualify if…
- ✓ HBsAg-negative by Abbott's HBsAg Test and HBeAg-negative;
- ✓ Having serum specimens retained at baseline and at 48 weeks off treatment follow up;
- ✓ Being willing to follow up regularly for 1 year.
You may not qualify if…
- ✕ Patients with hepatitis B cirrhosis in the compensated and decompensated stages: this includes patients with a clear history of cirrhosis (imaging or histological evidence) or Child-Pugh score ≥5 prior to NUC treatment, or who have had complications of the decompensated stage of cirrhosis, such as ascites, hepatic encephalopathy, or ruptured oesophago-gastric fundal varices bleeding;
- ✕ Combined HAV, HCV, HDV, HEV, HIV infections, alcoholic liver disease, inherited metabolic liver disease, pharmacological liver disease, non-alcoholic fatty liver disease, autoimmune liver disease and other chronic liver diseases;
- ✕ Primary hepatocellular carcinoma or those with AFP greater than 100 ng/ml at screening and imaging suggestive of possible malignant hepatic occupancy; or patients with AFP greater than 100 ng/ml for a sustained period of 3 months;
- ✕ Patients with a combination of other malignant tumours (excluding those who have been cured);
- ✕ Patients with severe diseases or uncontrolled disease
- ✕ Those who are also participating in other clinical studies;
- ✕ Patients deemed unsuitable by the investigator to participate in this study.
Source: ClinicalTrials.gov · NCT06550622 · last updated 2024-08-13